Nicotinamide Riboside Tested in Progressive Multiple Sclerosis
Tests a supplement against placebo in adults with progressive multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Key facts
- Where
- Bergen, NorwaySee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05740722, who can take part
Where in Norway
- Haukeland University HospitalBergen, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Haukeland University Hospital
- Trial code
- NCT05740722
- Record updated
- 11 January 2024
- Original description
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.Read full original descriptionShow less
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.
The main question it aims to answer is:
• Does NR delay disability progression in progressive multiple sclerosis?
Participants will be treated with NR or placebo for 30 months,
Inclusion: A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria; Aged 18-65 years; EDSS 3-6.5; Able to perform T25FW test; The participant must have documented evidence of disability progression observed during the 24 months before screening; With or without a stable disease modifying therapy during the last three months; Written informed consent for study participation.
Exclusion: Neoplastic disease at baseline; Previous history of malignant melanoma or breast cancer; Stable phase of a progressive disease course; Dementia or other neurodegenerative disorder at baseline visit; Comorbidity (psychiatric or somatic) that precludes study participation; Genetically confirmed mitochondrial disease or metabolic disorder; A diagnosis of relapsing MS according to the revisions of the McDonald criteria; Pregnancy or lactating female patients; Use of high dose vitamin B3 supplementation within 30 days of enrolment.